This is in line with a recent study that identified the E3 ubiquitin ligase NEDD4 as a key factor for PD-L1 degradation in FGFR3-activated cancer, providing a mechanistic link for potential drug combinations in the future [22]. This evidence concerns the gene NEDD4 and cancer.